Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053) | Zendy

Francesca Aweeka | Zendy; John G. Gambertoglio | Zendy; Chantal M.A.M. van der Horst | Zendy; Ralph H. Raasch | Zendy; Mark Z. Jacobson | Zendy

Open Access

Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)

Author(s) -

Francesca Aweeka,

John G. Gambertoglio,

Chantal M.A.M. van der Horst,

Ralph H. Raasch,

Mark Z. Jacobson

Publication year - 1992

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.36.8.1773

Subject(s) - zidovudine , foscarnet , pharmacokinetics , concomitant , medicine , liter , pharmacology , sida , human immunodeficiency virus (hiv) , virology , viral disease , herpesviridae

Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research